Oral propranolol is successful in treating periocular infantile haemangiomas.

Article

A study published in the Archives of Ophthalmology has confirmed the safety and efficacy of oral propranolol for the treatment of periocular infantile haemangiomas.

A study published in the Archives of Ophthalmology has confirmed the safety and efficacy of oral propranolol for the treatment of periocular infantile haemangiomas.

Dr Tara G. Missoi et al., Department of Ophthalmology, University of Missouri–Columbia, Missouri, USA, treated periocular hemangiomas from 17 children with oral propranolol 3 times a day. To document haemangioma, size serial examinations and external photography were used. The starting dose was 0.5mg for 1 week, then 1mg for 1 week and 2mg for the remainder of treatment.

Findings demonstrated that propranolol reduced the size of all infantile haemangiomas. Astigmatism was lowered by 33%, surface area reduced by 39% and vision was equalized in all but 1 child. The mean change in surface area was 61% of the original size. In 2 patients there was some rebound growth that did not require retreatment. Amblyopia was found in 7 patients and 1 patient experienced a benign episode of bradycardia.

Early use of propranolol is effective in treating and improving visual acuity in periocular infantile hemangiomas.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
© 2025 MJH Life Sciences

All rights reserved.